These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 38614074)
21. Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct? Ascierto PA; Daponte A; Giuseppe P Melanoma Res; 1999 Oct; 9(5):528-9. PubMed ID: 10596921 [No Abstract] [Full Text] [Related]
22. Active specific immunization in the treatment of patients with melanoma. Mastrangelo MJ; Maguire HC; Sato T; Nathan FE; Berd D Semin Oncol; 1996 Dec; 23(6):773-81. PubMed ID: 8970602 [TBL] [Abstract][Full Text] [Related]
23. An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis. Arabpour M; Paul S; Grauers Wiktorin H; Kaya M; Kiffin R; Lycke N; Hellstrand K; Martner A Oncoimmunology; 2022; 11(1):2115618. PubMed ID: 36046810 [TBL] [Abstract][Full Text] [Related]
24. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Eggermont AM; Ascierto PA; Khushalani NI; Schadendorf D; Boland G; Weber J; Lewis KD; Johnson D; Rivalland G; Khattak A; Majem M; Gogas H; Long GV; Currie SL; Chien D; Tagliaferri MA; Carlino MS; Diab A Future Oncol; 2022 Mar; 18(8):903-913. PubMed ID: 35073733 [TBL] [Abstract][Full Text] [Related]
25. Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. Letsch A; Keilholz U; Fluck M; Nagorsen D; Asemissen AM; Schmittel A; Thiel E; Scheibenbogen C Int J Cancer; 2005 May; 114(6):936-41. PubMed ID: 15645483 [TBL] [Abstract][Full Text] [Related]
26. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475 [TBL] [Abstract][Full Text] [Related]
27. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. Lattanzi M; Han J; Moran U; Utter K; Tchack J; Sabado RL; Berman R; Shapiro R; Huang HH; Osman I; Bhardwaj N; Pavlick AC J Immunother Cancer; 2018 May; 6(1):38. PubMed ID: 29773080 [TBL] [Abstract][Full Text] [Related]
28. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795 [TBL] [Abstract][Full Text] [Related]
29. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119 [TBL] [Abstract][Full Text] [Related]
30. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. Sondak VK; Liu PY; Tuthill RJ; Kempf RA; Unger JM; Sosman JA; Thompson JA; Weiss GR; Redman BG; Jakowatz JG; Noyes RD; Flaherty LE J Clin Oncol; 2002 Apr; 20(8):2058-66. PubMed ID: 11956266 [TBL] [Abstract][Full Text] [Related]
31. HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy. Bravo AI; Aris M; Panouillot M; Porto M; Dieu-Nosjean MC; Teillaud JL; Barrio MM; Mordoh J Front Immunol; 2023; 14():1231734. PubMed ID: 37691949 [TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA; Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502 [TBL] [Abstract][Full Text] [Related]
33. An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases. Mordoh A; Aris M; Carri I; Bravo AI; Podaza E; Pardo JCT; Cueto GR; Barrio MM; Mordoh J Front Immunol; 2022; 13():842555. PubMed ID: 35432383 [TBL] [Abstract][Full Text] [Related]
34. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Mahipal A; Terai M; Berd D; Chervoneva I; Patel K; Mastrangelo MJ; Sato T Cancer Immunol Immunother; 2011 Jul; 60(7):1039-45. PubMed ID: 21519827 [TBL] [Abstract][Full Text] [Related]
35. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Sondak VK; Sosman JA Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159 [TBL] [Abstract][Full Text] [Related]
36. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Lotem M; Peretz T; Drize O; Gimmon Z; Ad El D; Weitzen R; Goldberg H; Ben David I; Prus D; Hamburger T; Shiloni E Br J Cancer; 2002 May; 86(10):1534-9. PubMed ID: 12085200 [TBL] [Abstract][Full Text] [Related]
37. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses. Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ Front Immunol; 2022; 13():936129. PubMed ID: 36059502 [TBL] [Abstract][Full Text] [Related]
38. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123 [TBL] [Abstract][Full Text] [Related]
39. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878 [TBL] [Abstract][Full Text] [Related]
40. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C J Eur Acad Dermatol Venereol; 2023 May; 37(5):894-906. PubMed ID: 36433688 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]